Results 101 to 110 of about 4,164 (194)

Wnt/β-catenin pathway as a potential target for Parkinson’s disease: a cohort study of romosozumab using routinely collected health data in Japan

Frontiers in Pharmacology
IntroductionRomosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/β-catenin pathway. Given the essential roles of the Wnt/β-catenin pathway in various tissues, we hypothesized romosozumab ...
Shoichiro Inokuchi, Koji Shimamoto
doaj   +1 more source

A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis

Scientific Reports
We compared the efficacy of romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis in a randomized controlled trial.
Yasumori Sobue, Hironobu Kosugiyama, Shuji Asai, Yoshikazu Ogawa, Minoru Yoneda, Koji Maruyama, Mariko Kaneko, Tomonori Kobayakawa, Kenya Terabe, Mochihito Suzuki, Ryo Sato, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Masahiko Ando, Yachiyo Kuwatsuka, Naoki Ishiguro, Shiro Imagama   +17 more
doaj   +1 more source

Managing delayed union of fragility fractures of the pelvis successfully using romosozumab: A case report

Trauma Case Reports
Fragility fractures of the pelvis (FFPs) are typically caused by minor trauma or without any trauma in older individuals with osteoporosis. In recent years, FFP incidence has increased considerably owing to the increasing number of individuals in the ...
K. Wada, A. Tominaga, M. Naruo, K. Okazaki   +3 more
doaj   +1 more source

Bone mineral density response to romosozumab in post-menopausal women: A prospective observational real-world study [PDF]

Background: Romosozumab is approved in Europe for severe osteoporosis in postmenopausal women at high risk of fracture including older women, but whether bone mineral density (BMD) response varies with age remains unknown. Purpose: To examine BMD changes
Adami, Giovanni, Amini, Nadjia, Coppens, Désirée, De Vlam, Kurt, Dejaeger, Marian, Dupont, Jolan, Gielen, Evelien, Laurent, Michaël R, Rossini, Maurizio, Viapiana, Ombretta   +9 more
core   +1 more source

Utilization Of Romosozumab During Covid-19 Pandemic Among U.S. Medicare Beneficiaries [PDF]

Osteoporosis is increasingly recognized as a major public health issue in the aging U.S. population. Shortly after the licensure of romosozumab, an injectable medication indi-cated for women with postmenopausal osteoporosis at high risk of fracture ...
Liu, Ye
core   +1 more source

Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

PLoS ONE
IntroductionThis study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women.MethodsA Markov model ...
Juan Pablo Diaz Martinez, Therese Aubry de Maraumont, Elly Natty Sánchez, Luis Miguel Camacho Cordero, Eric Yeh   +4 more
doaj   +1 more source

Rationale and study design of a randomized controlled trial to investigate the effect of romosozumab on bone mineral density in hemodialysis patients with osteoporosis (the TRINITY study): A study protocol

Renal Replacement Therapy
Background Dialysis patients are at a high risk of fracture; however, little evidence is currently available regarding optimal treatment strategies. Romosozumab is a new drug for osteoporosis that promotes bone formation and inhibits bone resorption ...
Toshihiro Mizukoshi, Yachiyo Kuwatsuka, Masahiko Ando, Nobuhiro Nishibori, Hirotake Kasuga, Masato Tsuboi, Shoichi Maruyama, Sawako Kato   +7 more
doaj   +1 more source

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment

Biomedicines
Background/Objectives: Osteoporosis and cardiovascular disease (CVD) share common risk factors and pathophysiological mechanisms, raising concerns about the cardiovascular implications of sclerostin inhibition.
Shi-Hsun Chiu, Wen-Tien Wu, Ting-Kuo Yao, Cheng-Huan Peng, Kuang-Ting Yeh   +4 more
doaj   +1 more source

Osteoporosis Therapy: Bone Modeling during Growth and Aging [PDF]

, 2017
Hiromi Oda, Toshihiro Sugiyama
core   +1 more source

Cardiovascular risk assessment for osteoporosis patients considering Romosozumab [PDF]

Cardiovascular risk scoring tools are suitable for but not interchangeable within the osteoporosis clinic.
Bailey, S J, Clark, E M, Cockill, C, Faber, B G, Hardcastle, S, Macrae, F, Roy, M, Tobias, J H, Walsh, K   +8 more
core   +2 more sources